South Korea
· Delayed Price · Currency is KRW ilShinbiobase Statistics
Total Valuation
ilShinbiobase has a market cap or net worth of KRW 43.97 billion.
| Market Cap | 43.97B |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
ilShinbiobase has 41.68 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 41.68M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 32.82% |
| Owned by Institutions (%) | 0.22% |
| Float | 28.00M |
Valuation Ratios
The trailing PE ratio is 11.39.
| PE Ratio | 11.39 |
| Forward PE | n/a |
| PS Ratio | 2.46 |
| PB Ratio | 1.04 |
| P/TBV Ratio | 1.04 |
| P/FCF Ratio | 13.22 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.24
| Current Ratio | 5.24 |
| Quick Ratio | 3.80 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 8.06% and return on invested capital (ROIC) is 5.62%.
| Return on Equity (ROE) | 8.06% |
| Return on Assets (ROA) | 4.83% |
| Return on Capital (ROIC) | 5.62% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.39 |
| Inventory Turnover | 1.21 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -22.20% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -22.20% |
| 50-Day Moving Average | 1,146.94 |
| 200-Day Moving Average | 1,301.46 |
| Relative Strength Index (RSI) | 43.20 |
| Average Volume (20 Days) | 91,583 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ilShinbiobase had revenue of KRW 18.34 billion and earned 3.96 billion in profits. Earnings per share was 92.62.
| Revenue | 18.34B |
| Gross Profit | 8.45B |
| Operating Income | 3.68B |
| Pretax Income | 4.31B |
| Net Income | 3.96B |
| EBITDA | 4.25B |
| EBIT | 3.68B |
| Earnings Per Share (EPS) | 92.62 |
Balance Sheet
| Cash & Cash Equivalents | 19.03B |
| Total Debt | n/a |
| Net Cash | 19.03B |
| Net Cash Per Share | 456.69 |
| Equity (Book Value) | 42.38B |
| Book Value Per Share | 1,014.01 |
| Working Capital | 26.02B |
Cash Flow
In the last 12 months, operating cash flow was 4.27 billion and capital expenditures -943.94 million, giving a free cash flow of 3.33 billion.
| Operating Cash Flow | 4.27B |
| Capital Expenditures | -943.94M |
| Free Cash Flow | 3.33B |
| FCF Per Share | 79.81 |
Margins
Gross margin is 46.07%, with operating and profit margins of 20.06% and 21.58%.
| Gross Margin | 46.07% |
| Operating Margin | 20.06% |
| Pretax Margin | 23.51% |
| Profit Margin | 21.58% |
| EBITDA Margin | 23.20% |
| EBIT Margin | 20.06% |
| FCF Margin | 18.14% |
Dividends & Yields
This stock pays an annual dividend of 7.00, which amounts to a dividend yield of 0.66%.
| Dividend Per Share | 7.00 |
| Dividend Yield | 0.66% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 7.58% |
| Buyback Yield | 0.97% |
| Shareholder Yield | 1.64% |
| Earnings Yield | 8.78% |
| FCF Yield | 7.56% |
Stock Splits
The last stock split was on January 24, 2014. It was a forward split with a ratio of 5.
| Last Split Date | Jan 24, 2014 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
ilShinbiobase has an Altman Z-Score of 12.73.
| Altman Z-Score | 12.73 |
| Piotroski F-Score | n/a |